|
Indications and Dosage
Intramuscular
Active immunisation against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type B Child: ≥2 months to <5 years As primary immunisation: 2-3 doses of 0.5 mL to be given at least 1-month interval via deep inj into the anterolateral muscles of the thigh or the deltoid muscles of the upper arm. As booster immunisation: 0.5 mL at least 6 months after last dose. Refer to literature as dosage may vary with brand and local guidelines.
|
|
Contraindications
Hypersensitivity. History of encephalopathy within 7 days with pertussis vaccine. Progressive neurological disorder (e.g. infantile spasms, uncontrolled epilepsy, or progressive encephalopathy).
|
|
Special Precautions
Patient with family history of febrile convulsions, sudden infant death syndrome (SIDS); Guillain-Barre syndrome, ≥40.5°C temperature, hypotonic-hyporesponsive episode or crying for ≥3 hours within 48 hours or seizures within 3 days with pertussis vaccine; seizures, immunosuppression, severe febrile illness, bleeding disorder (e.g. thrombocytopenia).
|
|
Adverse Reactions
Significant: Fever (≥40.5°C temperature), hypotonic-hyporesponsive episode, inconsolable crying, irritability, seizures, syncope, Guillain-Barre syndrome, brachial neuritis; apnoea (premature infants).
Gastrointestinal disorders: Nausea, vomiting, diarrhea. General disorders and administration site conditions: Asthenia, fatigue, malaise, inj site reactions (e.g. tenderness, pain, oedema, erythema). Metabolism and nutrition disorders: Appetite loss. Nervous system disorders: Somnolence. Psychiatric disorders: Restlessness. Potentially Fatal: Hypersensitivity or anaphylaxis reactions. |
|
Monitoring Parameters
Monitor for signs of syncope for 15 minutes after injection.
|
|
Drug Interactions
Decrease effect with immunosuppressive agents (e.g. corticosteroids, antimetabolites).
|
|
Lab Interference
May interfere with urine antigen detection for Haemophilus influenzae type B infection for a week.
|
|
Action
Description:
Mechanism of Action: DTP-Hib-POL vaccine, a combination of diphtheria and tetanus toxoids and acellular pertussis, Haemophilus influenzae type B conjugate and inactivated poliovirus, promotes immunity against diphtheria, tetanus, pertussis, Haemophilus influenzae type B infection and poliomyelitis. |
|
Storage
Store between 2-8°C. Do not freeze.
Any unused portion should be disposed of in accordance with local requirements. |
|
MIMS Class
|
|
ATC Classification
J07CA06 - diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus ; Belongs to the class of combined bacterial and viral vaccines.
|
|
References
Anon. Diphtheria and Tetanus Toxoids, Acellular Pertussis, Poliovirus and Haemophilus b Conjugate Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 18/07/2018. Buckingham R (ed). Diphtheria, Tetanus, Pertussis, Poliomyelitis, and Haemophilus Influenzae Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/07/2018. Joint Formulary Committee. Diphtheria with Haemophilus Influenzae Type B Vaccine, Pertussis, Poliomyelitis and Tetanus. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/07/2018. Pentacel (Sanofi Pasteur, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 18/07/2018.
|
Sign Out
